Key points are not available for this paper at this time.
No need to pay if a drug doesn't work?Møldrup argues (p 1262) that not paying for a drug unless it works would not only benefit patients and healthcare funders, but it could also benefit drug manufacturers.He discusses the main tensions in the current marketing situation, explains the "no cure, no pay" strategy, and gives examples of some ways in which it has been implemented in the past decade.The strategy would also encourage therapeutic evaluations and reduce use of ineffective treatments, says the author, but he also acknowledges the need for more evidence and wider debate of the proposal.
Fiona Godlee (Thu,) studied this question.